9IB Stock Chart & Stats
€4.48
-€0.15(-3.23%)
At close: 4:00 PM EST
€4.48
-€0.15(-3.23%)
Day’s Range― - ―
52-Week Range€3.91 - €7.56
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€81.36M
Enterprise Value€545.68
Total Cash (Recent Filing)€131.93M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Aug 26, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.30
Shares Outstanding13,018,137
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)6.46
Price to Sales (P/S)0.00
P/FCF Ratio-9.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt capital structure materially reduces financial distress risk for a cash-burning biotech. It lowers fixed obligations and preserves flexibility to raise equity or partner non-dilutively, supporting long-term R&D investment capacity and survivability through development cycles.
Focused Microbiome R&D PlatformA narrow, science-driven focus on infant microbiome therapeutics targets high unmet medical need and creates potential for clinical and regulatory differentiation. Specialization can build enduring scientific know-how, IP and first-mover clinical data advantages in a defensible niche market.
Moderating Cash BurnSlowing cash outflows indicate improving operational discipline or milestone-driven cost control, which extends runway and increases probability of reaching key clinical inflection points before the next financing. This trend, if sustained, reduces near-term dilution risk.
Bears Say
Minimal Revenue And Persistent LossesNear-zero product revenue combined with large recurring operating losses is a structural weakness for a pre-commercial biotech. It implies long-term dependency on external capital, high execution risk to reach commercialization, and no current evidence of sustainable margins.
Sustained Negative Free Cash FlowPersistent negative FCF signals ongoing cash burn and recurring funding needs. Even with moderation, worsening free cash flow growth shows operations are not yet self-financing, creating dependence on capital markets or partners and increasing strategic vulnerability long term.
Declining Shareholder EquityA steep fall in equity reflects cumulative losses and value erosion, reducing the balance sheet cushion and limiting room to absorb setbacks. This constrains strategic options, increases dilution risk from future raises, and signals persistent failure to create shareholder value.
Infant Bacterial Therapeutics AB News
9IB FAQ
What was Infant Bacterial Therapeutics AB’s price range in the past 12 months?
Infant Bacterial Therapeutics AB lowest stock price was €3.91 and its highest was €7.56 in the past 12 months.
What is Infant Bacterial Therapeutics AB’s market cap?
Infant Bacterial Therapeutics AB’s market cap is €81.36M.
When is Infant Bacterial Therapeutics AB’s upcoming earnings report date?
Infant Bacterial Therapeutics AB’s upcoming earnings report date is Aug 26, 2026 which is in 28 days.
How were Infant Bacterial Therapeutics AB’s earnings last quarter?
Infant Bacterial Therapeutics AB released its earnings results on May 06, 2026. The company reported -€0.154 earnings per share for the quarter, missing the consensus estimate of -€0.127 by -€0.026.
Is Infant Bacterial Therapeutics AB overvalued?
According to Wall Street analysts Infant Bacterial Therapeutics AB’s price is currently Overvalued.
Does Infant Bacterial Therapeutics AB pay dividends?
Infant Bacterial Therapeutics AB does not currently pay dividends.
What is Infant Bacterial Therapeutics AB’s EPS estimate?
Infant Bacterial Therapeutics AB’s EPS estimate is -0.14.
How many shares outstanding does Infant Bacterial Therapeutics AB have?
Infant Bacterial Therapeutics AB has 13,018,137 shares outstanding.
What happened to Infant Bacterial Therapeutics AB’s price movement after its last earnings report?
Infant Bacterial Therapeutics AB reported an EPS of -€0.154 in its last earnings report, missing expectations of -€0.127. Following the earnings report the stock price went up 0.224%.
Which hedge fund is a major shareholder of Infant Bacterial Therapeutics AB?
Currently, no hedge funds are holding shares in DE:9IB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is based in Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Cantargia AB
―